PCVX

AI MemoPost-earnings T+3

Vaxcyte

As of 2026-08-17/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

OPUS-1 Phase 3 topline data remains the key near-term readout • 2026-11-15

Base target: $61 / p=50% prob

Biggest risk

The investment case remains dependent on binary clinical, manufacturing, regulatory, and competitive execution against established PCV20 and PCV21 products. Post-print analyst signals are mixed: Zacks was reported as upgrading PCVX from Strong Sell to Hold on August 12, while other tracked headlines included a Guggenheim Buy and a Wall Street Zen Sell; these are not a consistent consensus revision. [PCVX analyst ratings](https://www.pricetargets.com/NASDAQ/PCVX) [PCVX Q2 2026 earnings report](https://www.marketbeat.com/earnings/reports/2026-8-5-vaxcyte-inc-stock/)

Invalidation

Break below $39 or thesis failure.

What would change my mind?

The company source confirms a funded sequence of clinical milestones: adult VAX-31 studies are fully enrolled, OPUS-1 data are expected in Q4 2026, additional Phase 3 readouts are expected in 1H 2027, and liquidity was approximately $2.5 billion. The Q2 EPS result also modestly exceeded external consensus by $0.09, although revenue comparison was unavailable. [#PR-EARNINGS-2026-08-05] [PCVX Q2 2026 earnings report](https://www.marketbeat.com/earnings/reports/2026-8-5-vaxcyte-inc-stock/)

Research note

Recommendation

—

Confidence

medium

As of

2026-08-17

Base target

$61

p=50%

Bull target

$74

p=30%

Bear target

$39

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 EPS modestly beat external consensus
Recent insider sales may create a near-term sentiment overhang
Cash runway supports clinical and commercial-readiness execution

BearKey bullets

Clinical-stage cash burn and future financing could create dilution despite the current liquidity position.
Commercial positioning faces established PCV20 and PCV21 competitors.
External analyst reaction after the print was mixed, and no verified consensus target revision or estimate change is available.

WatchKey bullets

OPUS-1 Phase 3 topline data remains the key near-term readout

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $61 (p=50%)

Target spread vs base: +21% / -36%

Scenario probabilities

Bull Target: $74 (p=30%)Base Target: $61 (p=50%)Bear Target: $39 (p=20%)

Commentary

The Q2 company release provides concrete operating evidence and a modest external EPS beat, but the later post-earnings read-through remains mixed rather than decisively positive. Tracked analyst actions included both a Zacks upgrade and conflicting Buy/Sell coverage, while the available price record shows $58.07 at the August 14 close, down 1.34% that day, without a clean release-to-date attribution. Keep this as a cautious catalyst-monitoring situation rather than a high-conviction short-term trade. [#PR-EARNINGS-2026-08-05] [PCVX analyst ratings](https://www.pricetargets.com/NASDAQ/PCVX) [PCVX Q2 2026 earnings report](https://www.marketbeat.com/earnings/reports/2026-8-5-vaxcyte-inc-stock/)

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 EPS modestly beat external consensus
Recent insider sales may create a near-term sentiment overhang
Cash runway supports clinical and commercial-readiness execution

Scenarios

Bull Target (Scenario probability)

$74 / p=30% prob

Base Target (Scenario probability)

$61 / p=50% prob

Bear Target (Scenario probability)

$39 / p=20% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-11-15
OPUS-1 Phase 3 topline data remains the key near-term readout
The Q2 update says all three VAX-31 adult Phase 3 trials are fully enrolled and OPUS-1 topline safety, tolerability, and immunogenicity data are expected in Q4 2026, supporting the planned BLA path if successful. [#PR-EARNINGS-2026-08-05] [#SEC-8K-2026-08-05]
Prob 75.00% • Move 28.00% • Priced-in 45.00%
EVENT2026-11-15
OPUS-2 and OPUS-3 supportive Phase 3 readouts
Management expects results from the coadministration and previously vaccinated-adult studies in the first half of 2027; positive results could broaden label support and commercial positioning. [#PR-EARNINGS-2026-08-05]
Prob 68.00% • Move 18.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q2 EPS modestly beat external consensus
2026-08-05
Vaxcyte filed its Q2 results release in an 8-K; secondary earnings data report EPS of -$1.97 versus -$2.06 consensus, a $0.09 beat, while revenue comparison was unavailable. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-05] [PCVX Q2 2026 earnings report](https://www.marketbeat.com/earnings/reports/2026-8-5-vaxcyte-inc-stock/)
Prob 60% • Move 2% • Priced-in 75%
Recent insider sales may create a near-term sentiment overhang
2026-11-15
Recent Form 4 filings show open-market sales by senior officers, including the CEO and CFO. This is a secondary sentiment signal only and does not establish a change in operating performance. [#SEC-FORM4-2026-08-05] [#SEC-FORM4-2026-07-28]
Prob 60% • Move -4% • Priced-in 60%

Long-term Catalysts

Months to a year

Cash runway supports clinical and commercial-readiness execution
2027-08-17
Vaxcyte reported approximately $2.5 billion in cash, cash equivalents, and investments as of June 30, 2026, supporting execution into planned clinical, manufacturing, and commercial-readiness milestones, though the thesis remains development-stage and binary. [#PR-EARNINGS-2026-08-05]
Prob 80% • Move 10% • Priced-in 70%

Risks

Clinical-stage cash burn and future financing could create dilution despite the current liquidity position.
Commercial positioning faces established PCV20 and PCV21 competitors.
External analyst reaction after the print was mixed, and no verified consensus target revision or estimate change is available.
OPUS-1 could miss noninferiority, safety, tolerability, or immunogenicity objectives.
OPUS-1, OPUS-2, OPUS-3, the manufacturing-consistency study, BLA submission, or launch timing could be delayed.
Recent insider selling may weigh on short-term sentiment but is not evidence of operating deterioration.
The reported August 14 closing price was $58.07, down 1.34% that day, but the available source does not establish a clean release-to-date market reaction. [PCVX Q2 2026 earnings report](https://www.marketbeat.com/earnings/reports/2026-8-5-vaxcyte-inc-stock/)

Peers

Symbol	Summary
MRK	Direct operating comparator through Capvaxive, the approved PCV21 benchmark used in OPUS-1's head-to-head design. Merck is more useful as a commercial and competitive benchmark than as a like-for-like valuation peer because PCVX remains pre-commercial. [#PR-EARNINGS-2026-08-05] [#MRK-CAPVAXIVE]
PFE	Direct operating comparator through Prevnar 20, the incumbent PCV20 benchmark also used in OPUS-1. Pfizer is relevant for commercial positioning and standard-of-care comparison, but its scale and approved-product base make it a loose valuation comparator. [#PR-EARNINGS-2026-08-05] [#PFE-PREVNAR20]

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

MRK

Direct operating comparator through Capvaxive, the approved PCV21 benchmark used in OPUS-1's head-to-head design. Merck is more useful as a commercial and competitive benchmark than as a like-for-like valuation peer because PCVX remains pre-commercial. [#PR-EARNINGS-2026-08-05] [#MRK-CAPVAXIVE]

PFE

Direct operating comparator through Prevnar 20, the incumbent PCV20 benchmark also used in OPUS-1. Pfizer is relevant for commercial positioning and standard-of-care comparison, but its scale and approved-product base make it a loose valuation comparator. [#PR-EARNINGS-2026-08-05] [#PFE-PREVNAR20]